U.S. Physical Therapy, Inc. (USPH) Stock Forecast & Price Target
U.S. Physical Therapy, Inc. · NYSE
$79.17+2.53 (+3.30%)
15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 4 firms covering U.S. Physical Therapy, Inc, 4 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $90.00 to $102.00, so the covering firms are broadly aligned. The average target of $97.50 sits 23% above the current $79.17. The rating mix has stayed broadly stable, with Buy-side ratings edging up from 3 to 4 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.80 next quarter toward $3.41 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS4 ratings
Strong Buy
Strong Buy00%
Buy4100%
Hold00%
Sell00%
Strong Sell00%
Based on 4 analysts giving stock ratings to U.S. Physical Therapy, Inc.
As of Jul, 4 of 4 firms rate USPH a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
USPH EPS & revenue forecast
EPS · NEXT QUARTER
$0.80
Range $0.70 – $0.87 · 5 analysts · +21% YoY
Next period, 5 analysts expect U.S. Physical Therapy, Inc. to earn $0.80 a share (range $0.70 – $0.87), versus $0.66 a year earlier. Full-year consensus is $2.93, growing to $3.41 the year after.
REVENUE · NEXT QUARTER
$211.8M
Range $208.5M – $215.6M · 5 analysts · +7% YoY
Revenue is expected to reach $211.8M (range $208.5M – $215.6M), +7.4% year-over-year. Full-year consensus is $838.7M, rising to $895.7M next year.
Top analysts covering U.S. Physical Therapy, Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on USPH.
#1
Constantine Davides
JMP Securities · Rank #225
Buy
$98.00+23.8% to target
Overall win rate
34%
+ Follow
#2
Michael Petusky
Barrington Research · Rank #322
Buy
$90.00+13.7% to target
Overall win rate
29%
+ Follow
#3
CD
Constantine Davides
Citizens
Buy
$98.00+23.8% to target
Coverage
—
+ Follow
#4
BR
Benjamin Rossi
JP Morgan
Buy
$100.00+26.3% to target
Coverage
—
+ Follow
#5
CS
Calvin Sternick
JP Morgan
Buy
$110.00+38.9% to target
Coverage
—
+ Follow
USPH stock forecast FAQ
What is USPH's average 12-month price target?+
The 4 analysts with a live target average $97.50 for U.S. Physical Therapy, Inc. over the next 12 months, ranging from a $102.00 high to a $90.00 low.
Is USPH stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 4 analyst ratings, 4 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for USPH?+
The Street-high target is $102.00 (Jefferies), and the Street-low is $90.00 (Barrington Research). The average of all 4 active targets is $97.50.
How many Wall Street analysts cover USPH?+
4 analysts have an active rating on U.S. Physical Therapy, Inc., and 4 firms carry a live 12-month price target.
Who is the most accurate analyst covering USPH?+
Among analysts who currently cover USPH, Constantine Davides of JMP Securities has the strongest overall Quantellect track record (Rank #225). Their current call is Buy with a $98.00 target.
What is U.S. Physical Therapy, Inc.'s projected EPS for next quarter?+
The consensus estimate is $0.80 per share (range $0.70 – $0.87) across 5 analysts. Full-year EPS is projected at $2.93, rising to $3.41 the following year.
How much revenue is U.S. Physical Therapy, Inc. expected to report next quarter?+
Consensus revenue is $211.8M (range $208.5M – $215.6M). Full-year revenue is projected at $838.7M, growing to $895.7M next year.
Have analysts been upgrading or downgrading USPH lately?+
As of Jul, 4 of 4 firms rate USPH a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their USPH calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
